---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-25-000126"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:42:48.998037+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "low"
source: SEC EDGAR
---

# Recursion Q2 2025: $7M Sanofi milestone; REC-1245 and REC-617 trial updates

## Summary
- Announced $7 million milestone from Sanofi partnership for partnered discovery program.
- REC-1245 (RBM39) DAHLIA Phase 1/2 trial enrolling patients with tumors exhibiting replication stress and DDR vulnerabilities.
- REC-617 (CDK7 inhibitor) combination cohort to target platinum-resistant ovarian cancer using multi-omic and causal AI.
- Co-founder and CEO Chris Gibson highlighted platform advancements including Boltz-2 for ligand design.
- Exhibit text truncated; specific Q2 revenue, EPS, and cash position figures were not provided in the available excerpt.

## SEC filing metadata
- accession: 0001601830-25-000126
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: low
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183025000126/0001601830-25-000126-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183025000126/rxrx-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-25-000126
- JSON: https://secwatch.observer/filing/0001601830-25-000126.json
- Plain text: https://secwatch.observer/filing/0001601830-25-000126.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.